- Onychomycosis, a common fungal infection of the toenails or fingernails, leads to nail discoloration, thickening, and separation from the nail bed. It is primarily caused by dermatophytes, yeasts (like Candida), and non-dermatophyte molds
- The rising global burden of diabetes, peripheral vascular diseases, and immunosuppressive conditions has led to a higher incidence of onychomycosis, thereby fueling demand for effective pharmacological treatments
- Topical and oral antifungal drugs such as terbinafine, ciclopirox, griseofulvin, and ketoconazole are commonly used, with oral treatments offering higher cure rates but greater risk of systemic side effects
- North America holds a significant share of the market due to high disease awareness, availability of advanced treatment options, and favorable reimbursement policies
- Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by a large patient pool, improving access to healthcare, and growing consumer preference for dermatological treatments
- The Distal Subungual Onychomycosis segment expected to dominate the market with 35.55% shares. This dominance is attributed to its high prevalence among all age groups and its recognizable clinical features, making diagnosis and treatment more accessible. The segment's growth is further supported by increased awareness and availability of targeted therapies.
